Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carnoy solution is a chemical fixative and cauterizing agent originally developed by Jean-Baptiste Carnoy in the 19th century. The classic formulation consists of 60% ethanol, 30% chloroform, and 10% glacial acetic acid by volume, with some variants including ferric chloride. It is primarily used in histology for rapid fixation of tissues—especially for preserving glycogen and nucleic acids—and as a topical chemical cauterant after surgical removal of cysts or tumors (notably odontogenic keratocysts and ameloblastomas) to reduce recurrence rates. Its mechanism involves protein coagulation leading to superficial tissue necrosis at the application site[1][2][3][4][5]. Modified versions without chloroform are sometimes used due to concerns about chloroform’s carcinogenicity[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Carnoy solution.